Active substance
Results for the substance crovalimab
1 result
About this active substance
Crovalimab is a monoclonal antibody under investigation for the treatment of paroxysmal nocturnal hemoglobinuria (PNH) and other complement-mediated conditions. It works by inhibiting the C5 component of the complement system, preventing the destruction of red blood cells.
The medication is administered via subcutaneous injection or intravenous infusion, depending on the treatment protocol. The dose and frequency of administration are determined by the physician based on the patient's condition. Common side effects include injection site reactions, infections, and headaches.
Crovalimab is contraindicated in patients with active infections or hypersensitivity to the active substance. Patients should also be monitored to prevent the risk of severe infections, such as meningitis.
This medication represents a promising option for patients with PNH, helping to reduce symptoms and improve their quality of life.
The medication is administered via subcutaneous injection or intravenous infusion, depending on the treatment protocol. The dose and frequency of administration are determined by the physician based on the patient's condition. Common side effects include injection site reactions, infections, and headaches.
Crovalimab is contraindicated in patients with active infections or hypersensitivity to the active substance. Patients should also be monitored to prevent the risk of severe infections, such as meningitis.
This medication represents a promising option for patients with PNH, helping to reduce symptoms and improve their quality of life.